Corvus Advances Soquelitinib Trials with Positive Phase 1 Data and New Phase 2 Initiatives

Event summary

  • Corvus reported positive Phase 1 cohort 4 data for soquelitinib in atopic dermatitis and initiated a Phase 2 trial during Q1 2026.
  • New immunologic and biomarker data supporting drug-free remissions will be presented at the SID annual meeting on May 14, 2026.
  • Corvus plans to initiate Phase 2 trials for hidradenitis suppurativa and asthma later in 2026.
  • Cash reserves stood at $236.7 million as of March 31, 2026, expected to fund operations into Q2 2028.

The big picture

Corvus is positioning soquelitinib as a potential paradigm shift in immune disease treatment by targeting ITK inhibition. The company's strategic focus on expanding into multiple immune indications aligns with broader industry trends toward precision immunotherapy. With a robust cash position, Corvus aims to leverage its clinical pipeline to capture significant market share in atopic dermatitis and other immune-mediated conditions.

What we're watching

Clinical Efficacy
Whether soquelitinib's Phase 2 trial results will validate its potential for drug-free remissions in atopic dermatitis.
Market Expansion
The pace at which Corvus can expand soquelitinib into hidradenitis suppurativa and asthma indications.
Financial Runway
How Corvus will manage its cash reserves to sustain operations through 2028 amid increasing R&D expenses.